Feds charge Osiris execs with cooking the books as stock price soared
Investors might remember how interest in the stock of the little regenerative med biotech Osiris Therapeutics $OSIR hit a fever pitch in the summer of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
